CAJ | 학술논문

目的:探讨D2-40标记食管鳞癌淋巴管浸润(LVI)的临床病理意义.方法:应用免疫组织化学S-P法检测107例食管鳞癌D2-40蛋白表达并观察淋巴管受肿瘤细胞浸润的情况,分析其与食管鳞癌临床病理因素之间的关系,观察患者总生存期.结果:食管鳞癌组织LVI阳性组淋巴结转移率70%,LVI阴性组淋巴结转移率21%,LVI阳性组转移率高于阴性组,多因素分析显示两组间差异有统计学意义(P<0.001).LVI阳性组中位生存时间为26个月,LVI阴性组中位生存时间43个月,单因素分析显示两组间差异有统计学意义(P=0.014),多因素分析显示LVI不能成为食管鳞癌术后患者预后的独立危险因素(P=0.062),淋巴转移(P=0.031)、临床分期(P=0.019)和肿瘤残留(P=0.026)是预后的独立危险因素.结论:D2-40标记的LVI可以预测食管鳞癌患者的淋巴结转移.
목적:탐토D2-40표기식관린암림파관침윤(LVI)적림상병리의의.방법:응용면역조직화학S-P법검측107례식관린암D2-40단백표체병관찰림파관수종류세포침윤적정황,분석기여식관린암림상병리인소지간적관계,관찰환자총생존기.결과:식관린암조직LVI양성조림파결전이솔70%,LVI음성조림파결전이솔21%,LVI양성조전이솔고우음성조,다인소분석현시량조간차이유통계학의의(P<0.001).LVI양성조중위생존시간위26개월,LVI음성조중위생존시간43개월,단인소분석현시량조간차이유통계학의의(P=0.014),다인소분석현시LVI불능성위식관린암술후환자예후적독립위험인소(P=0.062),림파전이(P=0.031)、림상분기(P=0.019)화종류잔류(P=0.026)시예후적독립위험인소.결론:D2-40표기적LVI가이예측식관린암환자적림파결전이.
Objective:This study aims to investigate the clinicopathological significance of lymphatic vessel invasion (LVI) la-beled by D2-40 monoclonal antibody in esophageal squamous cell carcinoma (ESCC). Methods:Immunohistochemical assay was used to detect the expression of D2-40 and LVI in 107 ESCC cases. Then, the correlation between the clinicopathological feature and the overall survival time in patients was analyzed. Results:The lymph node metastasis rates were 70%and 21%in the LVI-positive and LVI-negative groups, respectively. The nodal metastasis rate was higher in the LVI-positive group than in the LVI-negative group. Mul-tivariate regression analyses showed that LVI was related to nodal metastasis (P<0.001). The median survival times of the patients were 26 and 43 months in the LVI-positive and LVI-negative groups, respectively. Although the univariate regression analysis showed signifi-cant difference between the two groups (P=0.014), the multivariate regression analyses revealed that LVI was not an independent prog-nostic factor for overall survival in the ESCC patients (P=0.062). Lymphatic node metastasis (P=0.031), clinical stage (P=0.019), and residual tumor (P=0.026) were the independent prognostic factors. Conclusion: LVI labeled by D2-40 monoclonal antibody is a risk factor predictive of lymph node metastasis in ESCC patients.